Margaret E Brousseau

Summary

Affiliation: Tufts University
Country: USA

Publications

  1. ncbi Common variation in genes involved in HDL metabolism influences coronary heart disease risk at the population level
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University and Department of Medicine, New England Medical Center, Boston, MA, USA
    Rev Endocr Metab Disord 5:343-9. 2004
  2. ncbi Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
    Margaret E Brousseau
    Lipid Research Laboratory, Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine, New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    N Engl J Med 350:1505-15. 2004
  3. ncbi Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial
    Margaret E Brousseau
    Lipid Metabolism Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, and Department of Medicine, New England Medical Center, Boston, MA, USA
    J Lipid Res 45:1885-91. 2004
  4. ncbi Emerging role of high-density lipoprotein in the prevention of cardiovascular disease
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA Human Nutrition Research Center on Aging, Tufts University, Tufts New England Medical Center, Boston, MA 02111, USA
    Drug Discov Today 10:1095-101. 2005
  5. ncbi Statins, super-statins and cholesterol absorption inhibitors
    Margaret E Brousseau
    JM USDA HNRCA at Tufts University, Lipid Metabolism Laboratory, 711 Washington Street, Boston, MA 02111, USA
    IDrugs 6:458-63. 2003
  6. ncbi ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption
    Margaret E Brousseau
    Tufts University School of Medicine, and Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Boston, Massachusetts 02111, USA
    Curr Opin Lipidol 14:35-40. 2003
  7. pmc Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA HNRCA at Tufts University and Tufts New England Medical Center, Boston, Mass 02111, USA
    Arterioscler Thromb Vasc Biol 25:1057-64. 2005
  8. pmc Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism
    Margaret E Brousseau
    Cardiovascular Research Laboratory, Tufts University School of Medicine, Boston, MA, USA
    J Lipid Res 50:1456-62. 2009
  9. ncbi A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, USA
    Atherosclerosis 180:407-15. 2005
  10. ncbi The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT)
    E Shyong Tai
    Nutrition and Genomics Unit, Jean Mayer USDA Human Nutrition Research Center for Aging at Tufts University, Boston, MA, USA
    Atherosclerosis 187:153-60. 2006

Detail Information

Publications26

  1. ncbi Common variation in genes involved in HDL metabolism influences coronary heart disease risk at the population level
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University and Department of Medicine, New England Medical Center, Boston, MA, USA
    Rev Endocr Metab Disord 5:343-9. 2004
  2. ncbi Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
    Margaret E Brousseau
    Lipid Research Laboratory, Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine, New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    N Engl J Med 350:1505-15. 2004
    ..Inhibition of cholesteryl ester transfer protein (CETP) has been proposed as a strategy to raise HDL cholesterol levels...
  3. ncbi Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial
    Margaret E Brousseau
    Lipid Metabolism Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, and Department of Medicine, New England Medical Center, Boston, MA, USA
    J Lipid Res 45:1885-91. 2004
    ....
  4. ncbi Emerging role of high-density lipoprotein in the prevention of cardiovascular disease
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA Human Nutrition Research Center on Aging, Tufts University, Tufts New England Medical Center, Boston, MA 02111, USA
    Drug Discov Today 10:1095-101. 2005
    ..Although they are at various stages of development, each of these therapies has promise for the treatment of cardiovascular disease in humans...
  5. ncbi Statins, super-statins and cholesterol absorption inhibitors
    Margaret E Brousseau
    JM USDA HNRCA at Tufts University, Lipid Metabolism Laboratory, 711 Washington Street, Boston, MA 02111, USA
    IDrugs 6:458-63. 2003
    ..This article reviews large-scale clinical trials in which statins have been used to reduce LDL-C concentrations. Studies that have examined the efficacy and safety of rosuvastatin, pitavastatin and ezetimibe will also be discussed...
  6. ncbi ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption
    Margaret E Brousseau
    Tufts University School of Medicine, and Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Boston, Massachusetts 02111, USA
    Curr Opin Lipidol 14:35-40. 2003
    ..The present review summarizes the most recent of these studies, as well as the only report to describe the effects of fatty acids on ATP-binding cassette transporter A1 gene activity...
  7. pmc Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA HNRCA at Tufts University and Tufts New England Medical Center, Boston, Mass 02111, USA
    Arterioscler Thromb Vasc Biol 25:1057-64. 2005
    ..The present study was designed to address these issues...
  8. pmc Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism
    Margaret E Brousseau
    Cardiovascular Research Laboratory, Tufts University School of Medicine, Boston, MA, USA
    J Lipid Res 50:1456-62. 2009
    ..Our findings indicate that CETP inhibition increases plasma concentrations of apoA-II by delaying HDL apoA-II catabolism and significantly alters the remodeling of apoA-II-containing HDL subpopulations...
  9. ncbi A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, USA
    Atherosclerosis 180:407-15. 2005
    ..We concluded that the CYP7A1 A-204C promoter variant was associated with poor response to atorvastatin, which were additively enhanced by common variants in another locus, APOE...
  10. ncbi The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT)
    E Shyong Tai
    Nutrition and Genomics Unit, Jean Mayer USDA Human Nutrition Research Center for Aging at Tufts University, Boston, MA, USA
    Atherosclerosis 187:153-60. 2006
    ..We hypothesized that the association between a functional polymorphism at the PPARA locus (L162V) and the risk of a CV event, as well as response to fibrate therapy, might be greatest in those with either IR or DM (DM/IR) in VA-HIT...
  11. ncbi Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    Atherosclerosis 175:287-93. 2004
    ..The other ABCG5/G8 polymorphisms did not show any significant interactions with the CYP7A1 polymorphism. We conclude that the ABCG8 H19 and CYP7A1 C-204 alleles appear to interact in a dose-dependent manner on atorvastatin response...
  12. ncbi ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    J Lipid Res 45:653-6. 2004
    ..These results suggest that, in patients with hypercholesterolemia, the ABCG8 D19H variant is associated with greater LDLC-lowering response to atorvastatin therapy...
  13. pmc Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease
    Gina M Peloso
    Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
    J Lipid Res 51:3524-32. 2010
    ....
  14. ncbi Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
    Atherosclerosis 178:331-8. 2005
    ....
  15. pmc Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism
    Margaret R Diffenderfer
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
    J Lipid Res 53:1190-9. 2012
    ..Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin...
  16. ncbi Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial
    Margaret E Brousseau
    Lipid Metabolism Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University and Department of Medicine, New England Medical Center, Boston, Mass 02111, USA
    Arterioscler Thromb Vasc Biol 22:1148-54. 2002
    ..The present study was undertaken to further define the relationship between this polymorphism and CHD risk at the population level...
  17. ncbi Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome
    Marcelo C Batista
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
    Metabolism 53:1255-61. 2004
    ....
  18. ncbi CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 93:104-7. 2004
    ....
  19. ncbi Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner
    Kouji Kajinami
    Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 93:1046-50. 2004
    ..Also, haplotype determination combined with these polymorphisms identified a subgroup that showed a striking response to treatment, which was not defined by a single polymorphism...
  20. ncbi New targets for medical treatment of lipid disorders
    Margaret E Brousseau
    JM USDA HNRCA at Tufts University, 711 Washington Street, Boston, MA 02111, USA
    Curr Atheroscler Rep 4:343-9. 2002
    ....
  21. ncbi In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II
    Minna L Hannuksela
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Atherosclerosis 165:205-20. 2002
    ..These differences were related to the lipid and apolipoprotein composition of the HDL subspecies, and, in control subjects, to the transfer of apoE from HDL subspecies to apoB-containing lipoproteins as well...
  22. ncbi Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
    John S Millar
    Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Lipid Res 49:543-9. 2008
    ..Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL...
  23. ncbi Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT)
    Angeliki Georgopoulos
    Medicine Service, Veterans Affairs Medical Center, Minneapolis, MN, USA
    Atherosclerosis 194:169-74. 2007
    ..0002). We conclude that based on the VA-HIT data, the Thr-54 polymorphism of the FABP2 gene is associated with a 2-3.5-fold increase in cardiovascular risk in dyslipidemic men with diabetes compared to their non-diabetic counterparts...
  24. ncbi Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans
    John S Millar
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Arterioscler Thromb Vasc Biol 26:1350-6. 2006
    ..The goal of the present study was to define the kinetic mechanism(s) by which CETP inhibition reduces levels of apoB-containing lipoproteins...
  25. ncbi ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease
    Sakari Kakko
    Department of Internal Medicine and Biocenter Oulu, University of Oulu, P O Box 5000, 90014, Oulu, Finland
    Atherosclerosis 166:285-90. 2003
    ..The G596A genotypes explained 4% and the A2589G genotypes 3% of the variation in plasma HDL-C levels in women. The data suggest that the ABCA1 locus is of minor importance in the regulation of HDL-C in Finns...
  26. ncbi Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management
    Kouji Kajinami
    Department of Cardiology, Kanazawa Medical University, 1 1 Daigaku, Uchinada 920 0293, Japan
    Atherosclerosis 177:219-34. 2004
    ....